)
Visual
test
Precigen
Precigen (PGEN) investor relations material
Precigen 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary15 Jan, 2026
Portfolio and Technology Advancements
Focus on differentiated cell and gene therapy platforms, including a proprietary gorilla adenovirus vector with high payload capacity, repeat dosing, and full IP protection.
Platform enables strong T cell immunity, minimal seropositivity, and supports multiple injections over years without loss of efficacy.
In-house manufacturing enables rapid development and commercialization.
Lead product (Pepcimeus/PAPZIMEOS) approved for recurrent respiratory papillomatosis (RRP), with additional candidates in phase II for HPV-related cancers.
Ongoing platform expansion through PRGN-2009 in head and neck and cervical cancers.
Commercialization and Market Execution
Pepcimeus/PAPZIMEOS received full FDA approval in August 2025 for all adult RRP patients, regardless of disease severity, shifting care from surgery to medical management.
U.S. commercial launch executed rapidly, with over 96% of target centers covered and strong payer uptake (170 million lives covered, ~80% of market).
Significant increase in brand awareness among physicians and patients within three months post-approval, with unaided awareness rising sharply in both academic and community settings.
Patient support hub established, with over 200 patients registered and parallel uptake through centers of excellence and community practices.
Broad FDA label allows use across all severities and stages of RRP, supporting early intervention and reducing irreversible damage.
Clinical Data and Patient Impact
Pivotal trials showed a 51% complete response rate, with complete responders having zero surgeries after four injections over three months and durable responses beyond three years.
Partial responders saw reduced surgery frequency; safety profile comparable to a flu shot.
Addresses a large unmet need: 27,000 U.S. patients, 35,000+ in Europe/Japan, 85,000+ in China.
Early and broad adoption driven by physician and patient demand to avoid surgical interventions and irreversible harm.
Enables repeat administration and is designed to generate a targeted immune response against HPV 6/11.
PAPZIMEOS payer coverage status?
PRGN-2009 next clinical development steps?
Target for positive cash flow?
What specific factors drove rapid payer coverage?
Explain AdenoVerse platform's regulatory advantage.
Provide a fair comp for PAPZIMEOS revenue trajectory.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- 7 FebPGIL
Strong 9MFY26 growth with 13.2% higher revenue, margin gains, and upgraded credit ratings. - 7 Feb504614
Strong revenue and profit growth in Q3 FY26, led by power and steel segments. - 7 FebCHEMPLASTS
Net losses widened and revenue fell year-over-year amid regulatory and market headwinds. - 7 FebSBIN
Q3 FY26 net profit reached ₹21,028.15 crore, driven by robust income and strategic divestments. - 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026.
Next Precigen earnings date
Q4 202519 Mar, 2026
Precigen
Next Precigen earnings date
Q4 202519 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Precigen Inc is an innovator in the discovery and development of next-generation gene and cell therapies, with a mission to enhance the lives of patients through transformational technologies. The company operates in two segments, Precigen, Inc. and Cell Therapy Systems (CTS). The Precigen, Inc. segment discovers and develops the next generation of gene and cellular therapies that address medical needs in cancer, infectious disease and immunological disorders.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage